ArticleMagnetic resonance in medicine2010
Novel membrane-permeable contrast agent for brain tumor detection by MRI.
Article in Magnetic resonance in medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 35 citations in OpenAlex.
- Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models.Journal of functional biomaterials · 2025Article
- Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases.Journal of visualized experiments : JoVE · 2024Article
- Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide.International journal of nanomedicine · 2021Article
- Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS Tumors.Frontiers in immunology · 2021Review
- Novel delivery approaches for cancer therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ.Molecular imaging and biology · 2014Article
- The application of magnetic nanoparticles for the treatment of brain tumors.Frontiers in chemistry · 2014Article
- Materials characterization of Feraheme/ferumoxytol and preliminary evaluation of its potential for magnetic fluid hyperthermia.International journal of molecular sciences · 2013Article
- Nanoparticles for imaging and treating brain cancer.Nanomedicine (London, England) · 2013Review
- Altering iron oxide nanoparticle surface properties induce cortical neuron cytotoxicity.Chemical research in toxicology · 2012Article
- Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers.Advanced materials (Deerfield Beach, Fla.) · 2011Review
- Magnetite Nanoparticles for Medical MR Imaging.Materials today (Kidlington, England) · 2011Article
- siRNA delivery to CNS cells using a membrane translocation peptide.Bioconjugate chemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
One of the key challenges hindering the clinical intervention against brain cancer is defined by the inability to detect brain tumors at an early enough stage to permit effective therapy. Furthermore, the rapid growth and severe lethality of this form of cancer predicate the vital importance of monitoring the development of the pathology and its outcome after therapeutic intervention. With this in mind, we designed a novel membrane-permeant contrast agent, MN-MPAP-Cy5.5, which consists of a superparamagnetic iron oxide core, for MRI conjugated to myristoylated polyarginine peptides, as a membrane translocation module and labeled with the near-infrared dye Cy5.5 for correlative microscopy. This probe showed a remarkable uptake by U-87 human glioma cells in vitro and localized and delineated stereotactically injected tumor in vivo by MRI. Our findings suggest that the agent mediates its effects by translocation of the magnetic nanoparticles label across the leaky tumor vasculature, followed by enhanced accumulation in tumor cells. The noninvasive detection of brain tumors when they are still small represents a formidable challenge from an imaging standpoint. Our study describes an improved strategy to detect brain lesions by utilizing a contrast agent with membrane translocation properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.